Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.
Qlaris Bio has raised $24.0M in total funding. The most recent round was Series B. The last funding was announced in April 2024.
Qlaris Bio's investors include Correlation Ventures, Canaan Partners, Aberdeen, New Leaf Venture Partners, Mayo Clinic Ventures.
Qlaris Bio is headquartered in Wellesley, United States.
Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.
Qlaris Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Qlaris Bio — Funding & Investors." VCBacked, April 22, 2024, https://www.vcbacked.co/company/qlaris-bio. Accessed July 19, 2026.
VCBacked. (2024). Qlaris Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/qlaris-bio
{{cite web |title=Qlaris Bio — Funding & Investors |url=https://www.vcbacked.co/company/qlaris-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated